We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01385787
Recruitment Status : Completed
First Posted : June 30, 2011
Last Update Posted : September 7, 2017
Information provided by (Responsible Party):

June 28, 2011
June 30, 2011
September 7, 2017
October 2011
May 2017   (Final data collection date for primary outcome measure)
Two-year Event Free Survival (EFS) [ Time Frame: 2 years post-HCT ]
Event-free survival is defined as the time from HCT to relapse, death, initiation of post-HCT therapy to treat AML relapse, loss to follow up or end of study whichever comes first.
Not Provided
Complete list of historical versions of study NCT01385787 on ClinicalTrials.gov Archive Site
  • Two-year overall survival (OS) [ Time Frame: 2 years post-HCT ]
    Overall survival is the time from HCT to death from any cause, loss to follow up or end of study, whichever comes first.
  • Disease relapse at 2 years [ Time Frame: 2 years post-HCT ]
    Relapse includes morphologic reappearance of leukemia or treatment for impending relapse. Death in remission is a competing risk. Relapse is defined as in 3.1. Cytogenetic or molecular relapse with <5% leukemic blasts in the bone marrow does not constitute a relapse unless unplanned AML-directed therapy is administered.
  • Occurrence of acute grade II-IV and grade III-IV GVHD by 200 days post-HCT [ Time Frame: 200 days post-HCT ]
    Any skin, gastrointestinal or liver abnormalities fulfilling the consensus criteria [36] of grades II-IV or grades III-IV acute GVHD are considered events. Death and second transplants are competing risks, and patients alive without acute GVHD will be censored at the time of last follow-up.
  • Occurrence of chronic GVHD at 2 years post-HCT [ Time Frame: 2 years post-HCT ]
    Occurrence of any symptoms in any organ system fulfilling the CIBMTR criteria of limited or extensive chronic GVHD. Death and the second transplant are competing risks, and patients alive without chronic GVHD will be censored at time of last follow-up.
  • Time to neutrophil engraftment [ Time Frame: 42 days post-HCT ]
    1st consecutive day of a sustained ANC ≥ 500/ μL for 3 consecutive days. Death without engraftment and second transplants are considered competing risks.
  • Time to platelet engraftment [ Time Frame: 42 days post-HCT ]
    1st day of platelet count ≥20,000/μL that persists ≥7 days, without transfusion. Death without engraftment and second transplants are considered competing risks.
  • Veno-occlusive Disease [ Time Frame: 2 years post-HCT ]
    Cumulative incidence of veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS), with median maximum bilirubin for subjects diagnosed with VOD/SOS. Subjects classified as having had VOD/SOS must meet the Jones Criteria, defined as: bilirubin>2mg/dL and at least 2 of the following signs: a) hepatomegaly and/or right upper quadrant pain, and b) >5% weight gain.
  • Chimerism [ Time Frame: 100 days post-HCT ]
    Whole blood chimerism and T-cell chimerism will be classified according to full (>95%), mixed (5-95%), or none (<5%) at 100 days.
Not Provided
Not Provided
Not Provided
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
The Role of Minimal Residual Disease Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
This is a non-therapeutic study. Pediatric AML patients undergoing HCT with a myeloablative preparative regimen may be enrolled. Subjects can be enrolled 10-40 days prior to HCT. Three samples for MRD (measured by WT1 PCR and flow cytometry) will be collected from peripheral blood and bone marrow: 1) pre-HCT (<3 weeks prior to starting the preparative regimen), 2) day 42 +/- 14 days post HCT (early post-engraftment), and 3) day 100 (+/-20 days) post HCT. For two years after transplant, the subject's follow-up data will be collected using the Research Level Forms in the CIBMTR Forms Net internet data entry system. The main objective is to determine whether there is any association between level of pre-transplant and post-transplant bone marrow MRD using WT1 and flow cytometry with 2-year event-free-survival, and to estimate the strength of that association in terms of the predictive accuracy of MRD. The investigators hypothesize that measurable MRD at either time point will be associated with decreased 2-year event-free survival.

This is a prospective, non-therapeutic study, assessing the significance of minimal residual disease (MRD) at three different time points in relation to allogeneic HCT for pediatric AML. The study is a collaboration between the Pediatric Blood and Marrow Transplant Consortium (PBMTC) and the Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT) of the Center for International Blood and Marrow Transplant Research (CIBMTR). The study will enroll pediatric AML patients who undergo myeloablative HCT at PBMTC sites. The eligibility criteria for this non-therapeutic study mirror widely accepted criteria for allogeneic HCT in pediatric AML.

The study tests the hypothesis that assessment of pre-transplant and post-transplant MRD predicts 2-year outcomes following transplant. Two MRD methodologies are being studied: flow cytometry and WT1 PCR. The secondary hypothesis is that combining these 2 methodologies will improve the accuracy in predicting 2-year outcomes following transplant.

It is well established that the level of minimal residual disease (MRD) during chemotherapy is a strong predictor of relapse in children with acute lymphoblastic leukemia (ALL) [33, 34]. Within this population, MRD levels have the potential to predict those patients who will respond well to standard therapy, thus allowing clinicians to tailor therapy and minimize toxicity while ensuring maximal cure rates [10]. MRD levels before allogeneic hematopoietic stem cell transplantation (HCT) also predict the risk of relapse post-HCT [25], leading to the clinical practice of reducing MRD levels as much as possible before transplant. By contrast, in children with acute myeloid leukemia (AML), the prognostic value of MRD levels prior to HCT remains unclear.

Our long-term objective is to improve the cure rate for children with AML. The investigators hypothesize that MRD levels before HCT will provide a powerful tool to select the best candidates for transplant, guide decision making in stem cell source and preparative therapy, and optimize the timing of the transplant. Measurements of MRD post-HCT will allow informed decisions about withdrawal of immunosuppressive therapy, administration of donor lymphocyte infusions, or alternative targeted therapies.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Participating institutions (transplant centers)
Acute Myeloid Leukemia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
May 2017
May 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subject or legal guardian to understand and voluntarily sign an informed consent.
  2. Age 0-21 at time of transplant.
  3. Karnofsky score ≥ 70% (age ≥ 16 years old), or Lansky score ≥ 70% (age<16 years old).
  4. Patients with adequate physical function as measured by:

    • Cardiac: Left ventricular ejection fraction at rest must be > 40%, or shortening fraction > 26%
    • Hepatic: Bilirubin ≤ 2.5 mg/dL; and ALT, AST and Alkaline Phosphatase≤ 5 x ULN
    • Renal: Serum creatinine within normal range for age, or if serum creatinine outside normal range for age, then renal function (creatinine clearance or GFR) > 70 mL/min/1.73 m2.
    • Pulmonary: DLCO, FEV1, FVC (diffusion capacity) > 50% of predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, then O2 saturation > 92% in room air.
  5. Acute myelogenous leukemia (AML) at the following stages:

    • High risk first complete remission (CR1), defined as:

      • Having preceding myelodysplasia (MDS) -or-
      • Diagnostic high risk karyotypes: del (5q) -5, -7, abn (3q), t (6;9), abnormalities of 12, t (9:22), complex karyotype (≥3 abnormalities), the presence of a high FLT3 ITD-AR (> 0.4) -or-
      • Having >15% bone marrow blasts after 1st cycle and/or >5% after 2nd cycle before achieving CR -and-
      • <5% blasts in the bone marrow, with peripheral ANC>500
    • Intermediate risk first complete remission (CR1), defined as:

      • Diagnostic karyotypes that are neither high-risk (as defined above) nor low risk (inv(16)/t(16:16); t(8;21); t(15;17)). Included are cases where cytogenetics could not be performed. -and-
      • <5% blasts in the bone marrow, with peripheral ANC>500
    • High risk based upon COG AAML 1031 criteria:

      • High allelic ratio FLT3/ITD+, monosomy 7, del(5q) with any MRD status or standard risk cytogenetics with positive MRD at end of Induction I.
      • <5% blasts in the bone marrow, with peripheral ANC>500
    • Second or greater CR

      • <5% blasts in the bone marrow, with peripheral ANC>500
    • Therapy-related AML at any stage

      • Prior malignancy in remission for >12 months.
      • <5% blasts in the bone marrow, with peripheral ANC>500
  6. Myeloablative preparative regimen, defined as a regimen including one of the following as a backbone agent*:

    • Busulfan ≥ 9mg/kg total dose (IV or PO). PK-based dosing is allowed, if intent is myeloablative dosing OR
    • Total Body Irradiation≥1200cGy fractionated OR
    • Treosulfan ≥ 42g/m2 total dose IV *Regimens may include secondary agents such as, but not limited to Ara-C, Fludarabine, VP-16. Regimens that combine Busulfan and TBI or treosulfan and TBI are allowed as long as the Busulfan or treosulfan meets or exceeds the dose listed and the TBI is below the dose listed.
  7. Graft source:

    • HLA-identical sibling PBSC, BM, or cord blood
    • Adult related or unrelated donor PBSC or BM matched at the allelic level for HLA-A, HLA-B, HLA-C, and HLA-DRB1 with no greater than a single antigen mismatch.
    • One or two unrelated cord blood units:

      • HLA≥4:6 at the low resolution level for HLA-A, HLA-B, at high resolution level at HLA-DRB1 for one or both units.
      • If one unit, must have TNC≥2.5x107/kg; if two units, combination of the two must have TNC≥2.5x107/kg

Exclusion Criteria:

  1. Women who are pregnant (positive HCG) or breastfeeding.
  2. Evidence of HIV infection or HIV positive serology.
  3. Positive viral load (PCR) for Hepatitis B or C (negative serology, surface antigen, and core antibody may substitute for PCR).
  4. Current uncontrolled bacterial, viral or fungal infection (currently taking medication and progression of clinical symptoms).
  5. Autologous transplant < 12 months prior to enrollment.
  6. Prior allogeneic hematopoietic stem cell transplant.
Sexes Eligible for Study: All
up to 21 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
Not Provided
Not Provided
Center for International Blood and Marrow Transplant Research
Center for International Blood and Marrow Transplant Research
  • Pediatric Blood and Marrow Transplant Consortium
  • St. Baldrick's Foundation
  • Otsuka Pharmaceutical Development & Commercialization, Inc.
Principal Investigator: David A. Jacobsohn, MD, ScM Children's Research Institute
Center for International Blood and Marrow Transplant Research
September 2017